CStone Pharmaceuticals

HKSE 2616.HK

CStone Pharmaceuticals Return on Capital Employed (ROCE) for the year ending December 31, 2023: -43.79%

CStone Pharmaceuticals Return on Capital Employed (ROCE) is -43.79% for the year ending December 31, 2023, a 66.12% change year over year. Return on capital employed assesses profitability against invested capital; higher ROCE signals efficient capital use.

CStone Pharmaceuticals Return on Capital Employed (ROCE) for the year ending December 31, 2022 was -129.23%, a 9.81% change year over year.
CStone Pharmaceuticals Return on Capital Employed (ROCE) for the year ending December 31, 2021 was -143.28%, a -256.62% change year over year.
CStone Pharmaceuticals Return on Capital Employed (ROCE) for the year ending December 31, 2020 was -40.18%, a 42.35% change year over year.
CStone Pharmaceuticals Return on Capital Employed (ROCE) for the year ending December 31, 2019 was -69.69%.

Key data

Date	Return on Capital Employed (ROCE)	Interest Coverage Ratio	Debt to Equity Ratio	Return on Common Equity

HKSE: 2616.HK

CStone Pharmaceuticals

CEO	Dr. Jianxin Yang M.D., Ph.D.
IPO Date	Feb. 26, 2019
Location	China
Headquarters	New Bund Times Square
Employees	164
Sector	Healthcare
Industries Biotechnology 3D Printing Clinical Trials Pharmaceuticals Robotics Vaccines

Description

CStone Pharmaceuticals, a biopharmaceutical company, researches, develops, and commercializes immuno-oncology and precision medicines to address the unmet medical needs of cancer patients in China and internationally. It offers Sugemalimab, a monoclonal antibody against programmed death (PD) ligand 1; GAVRETO, an RET inhibitor for the treatment of patients with advanced or metastatic RET-mutant medullary and RET fusion-positive thyroid cancers; and avapritinib, a KIT/PDGFRA inhibitor to treat adults with unresectable or metastatic gastrointestinal stromal tumors harboring a PDGFRA exon 18 mutation. The company's product pipeline includes Nofazinlimab, a PD-1 antibody for the treatment of patients with hepatocellular carcinoma; Ivosidenib, an isocitrate dehydrogenase 1 (IDH1) inhibitor to treat adults with relapsed or refractory acute myeloid leukemia with an IDH1 mutation; and Fisogatinib, an FGFR4 inhibitor to treat hepatocellular carcinoma. Its products also comprise CS1002, CS2006, CS3002, CS3005, CS2007, CS2008, and CS500 for solid tumors; and CS5001 for solid tumors and hematologic malignancies. The company was incorporated in 2015 and is headquartered in Shanghai, China.

Key trends

Past 5 years